Technologies
Advanced Chip-based Photonic microscopy for virus research
COMBAT will use the Advanced Chip-based Photonic (ACP) microscopy platform developed by Chip NanoImaging AS for high-performance imaging of biological samples. The ACP ZERO is a simple-to-use upright TIRF microscopy system that replaces conventional microscope glass slides with photonic waveguide technology to provide simultaneous sample support and illumination.
The ACP technology outperforms traditional TIRF microscopes by offering ultrawide fields of view, eliminating technical complexities, and reducing time-consuming setup, maintenance, and calibration. Moreover, the photonic waveguide technology ensures a well-defined sample illumination that improves the signal-to-noise ratio by minimizing the out-of-focus light. The chip-TIRF technology provides multi-color imaging at different magnifications, positioning it as an ideal platform for detailed visualizations of dynamic host-virus interactions, including viral entry, replication, and intracellular trafficking. Its large field of view and super-resolution capabilities facilitate the statistical significance of microscopy data in viral spread studies, host protein responses, and drug screening while allowing real-time visualization of such processes.
Advancing Research with MIVO® Organ-on-Chip Technology
MIVO® (Multi In Vitro Organ) is an innovative organ-on-chip platform designed to replicate human organ functions in a controlled, dynamic environment. By introducing fluid flow to static tissue models, MIVO® mimics the natural physiological conditions of the human body, enabling researchers to study biological processes with greater
accuracy and relevance.
This advanced technology allows the continuous perfusion of nutrients, drugs, and metabolites, simulating the dynamic interactions that occur in living systems. This capability provides deeper insights into tissue regeneration, disease progression, and the effects of therapeutic interventions. By incorporating fluid dynamics, MIVO® also
supports the study of key physiological processes such as drug absorption, immune responses, and cell-to-cell communication.
MIVO® is highly versatile, accommodating various tissue types and enabling multi-organ interactions for complex biological studies. Its ability to replicate human biology more reliably than static models or animal testing accelerates drug development, toxicity testing, and disease modeling, offering a predictive alternative that reduces experimental uncertainties.
By bridging the gap between static in vitro systems and real physiological conditions, MIVO® empowers researchers to generate impactful results that drive innovation across biotechnology, pharmaceuticals, and healthcare, fostering the development of safer and more effective treatments.
Learn more at https://www.react4life.com/mivo-technology/
PEA (Proximity Extension Assay) technology for protein analysis
PEA (Proximity Extension Assay) technology has revolutionized protein analysis by enabling highly specific and sensitive detection of proteins in complex biological samples. Unlike traditional methods, PEA allows for simultaneous analysis of hundreds of proteins with minimal sample volume, significantly improving the speed and depth of proteomic research. Its unique antibody-based approach ensures high accuracy, even in low-abundance proteins, making it a game-changer in identifying biomarkers and understanding disease mechanisms at a molecular level.
Sensitivity: 99.5% of our 5,400+ protein biomarkers display no cross-reactivity. That means no wrong targets, no misinterpretation, and no wasted time or money.
Specificity: The paired antibodies binding to target proteins ensure that only specific protein interactions are detected, reducing background noise and increasing the accuracy of results.
Scalability: A concordance study showed high correlations for the same proteins across all Olink products, enabling a seamless transition from discovery to clinical utility without performance loss.
Simplicity: Our streamlined workflows, bespoke data analysis software, and extensive quality control allow you to derive actionable insights from trusted data—so your research can go further and faster.
In COMBAT, we aim to identify the early predictive biomarkers for dengue severity first by using the Olink® Explore series, followed by developing an Olink® Flex panel of dengue severity that will be tested in several cohorts from Central America and Southeast Asia.